Has the Swiss Pharma Industry valuation changed over the past few years?

Investors are relatively neutral on the Swiss Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady. The industry is trading close to its 3-year average PE ratio of 22.5x. The 3-year average PS ratio of 3.9x is lower than the industry's current PS ratio of 4.5x.

Which industries have driven the changes within the Swiss Healthcare industry?

There are no additional sub-industries under this industry.

Swiss (SMI) Pharma Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Mon, 22 Jun 2026	CHF 547.0b	CHF 122.8b	CHF 25.1b	39.9x	21.8x	4.5x
Wed, 20 May 2026	CHF 561.2b	CHF 121.5b	CHF 24.8b	39.2x	22.6x	4.6x
Fri, 17 Apr 2026	CHF 545.3b	CHF 121.1b	CHF 25.1b	39.5x	21.7x	4.5x
Sun, 15 Mar 2026	CHF 554.6b	CHF 121.7b	CHF 25.2b	37.1x	22x	4.6x
Tue, 10 Feb 2026	CHF 581.6b	CHF 119.2b	CHF 24.2b	37.6x	24x	4.9x
Thu, 08 Jan 2026	CHF 579.2b	CHF 121.2b	CHF 21.5b	36.4x	26.9x	4.8x
Sat, 06 Dec 2025	CHF 541.5b	CHF 121.8b	CHF 21.7b	33.9x	25x	4.4x
Mon, 03 Nov 2025	CHF 476.7b	CHF 121.7b	CHF 21.6b	32.4x	22x	3.9x
Wed, 01 Oct 2025	CHF 475.4b	CHF 120.1b	CHF 20.9b	31.4x	22.7x	4x
Fri, 29 Aug 2025	CHF 481.0b	CHF 120.5b	CHF 21.0b	30.6x	22.9x	4x
Sun, 27 Jul 2025	CHF 460.3b	CHF 119.9b	CHF 20.7b	23.3x	22.2x	3.8x
Tue, 24 Jun 2025	CHF 445.4b	CHF 118.3b	CHF 19.1b	25x	23.3x	3.8x
Thu, 22 May 2025	CHF 440.6b	CHF 119.2b	CHF 19.3b	25.2x	22.9x	3.7x
Sat, 19 Apr 2025	CHF 413.0b	CHF 117.3b	CHF 18.4b	24.6x	22.4x	3.5x
Mon, 17 Mar 2025	CHF 476.6b	CHF 121.8b	CHF 19.2b	29.4x	24.9x	3.9x
Wed, 12 Feb 2025	CHF 476.5b	CHF 123.3b	CHF 19.3b	22.7x	24.7x	3.9x
Fri, 10 Jan 2025	CHF 448.5b	CHF 119.8b	CHF 21.5b	18.7x	20.9x	3.7x
Sun, 08 Dec 2024	CHF 428.1b	CHF 117.7b	CHF 21.1b	18.3x	20.3x	3.6x
Tue, 05 Nov 2024	CHF 451.9b	CHF 116.7b	CHF 20.9b	19.6x	21.6x	3.9x
Thu, 03 Oct 2024	CHF 448.6b	CHF 114.6b	CHF 19.3b	21.4x	23.3x	3.9x
Sat, 31 Aug 2024	CHF 478.3b	CHF 114.9b	CHF 19.3b	22.8x	24.8x	4.2x
Mon, 29 Jul 2024	CHF 463.8b	CHF 116.7b	CHF 19.7b	22.1x	23.6x	4x
Wed, 26 Jun 2024	CHF 437.0b	CHF 116.2b	CHF 19.7b	33.7x	22.1x	3.8x
Fri, 24 May 2024	CHF 413.3b	CHF 117.4b	CHF 19.9b	42.7x	20.7x	3.5x
Sun, 21 Apr 2024	CHF 398.4b	CHF 112.4b	CHF 19.5b	36.9x	20.5x	3.5x
Tue, 19 Mar 2024	CHF 388.1b	CHF 111.2b	CHF 19.3b	37.5x	20.1x	3.5x
Thu, 15 Feb 2024	CHF 378.4b	CHF 110.7b	CHF 19.7b	23.6x	19.2x	3.4x
Sat, 13 Jan 2024	CHF 415.7b	CHF 119.4b	CHF 18.7b	27.1x	22.3x	3.5x
Mon, 11 Dec 2023	CHF 401.6b	CHF 121.2b	CHF 18.9b	24.3x	21.3x	3.3x
Wed, 08 Nov 2023	CHF 385.2b	CHF 122.5b	CHF 19.1b	23.6x	20.2x	3.1x
Fri, 06 Oct 2023	CHF 399.8b	CHF 113.6b	CHF 18.2b	42.6x	22x	3.5x
Sun, 03 Sep 2023	CHF 405.5b	CHF 112.1b	CHF 18.0b	48.3x	22.6x	3.6x
Tue, 01 Aug 2023	CHF 418.1b	CHF 114.5b	CHF 19.2b	48.9x	21.7x	3.7x
Thu, 29 Jun 2023	CHF 415.9b	CHF 115.2b	CHF 18.9b	36.7x	22x	3.6x


CH Market	0.72%
Healthcare	-1.85%
Pharma	-2.57%
Pharma	-2.57%

Company	Last Price	7D	1Y	Valuation
SDZ Sandoz Group	CHF 67.92	1.3% +CHF 380.8m	55.7%	PE39.9x
DESN Dottikon ES Holding	CHF 303.50	4.3% +CHF 172.7m	6.3%	PE40.5x
GALD Galderma Group	CHF 172.40	0.1% +CHF 58.6m	53.8%	PE81.8x
BIOV BioVersys	CHF 27.00	3.1% +CHF 4.7m	-23.3%	PS49.8x
NWRN Newron Pharmaceuticals	CHF 12.20	1.2% +CHF 2.9m	71.6%	PS14.4x

Announcement • Jun 18

Roche Receives FDA Acceptance for Supplemental Biologics License Application For Lunsumio And Polivy Combination For Relapsed Or Refractory Large B-Cell Lymphoma

Roche announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Lunsumio VELO (mosunetuzumab), as a subcutaneous formulation, in combination with Polivy (polatuzumab vedotin) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL), after at least one prior line of systemic therapy. The FDA is expected to make a decision on approval by 9 February 2027. The sBLA acceptance is based on results from the phase III SUNMO study. At a median follow-up of 23.2 months, the Lunsumio VELO and Polivy combination demonstrated a 59% reduction in risk of disease progression or death (progression-free survival [PFS]) compared to MabThera/Rituxan (rituximab), gemcitabine and oxaliplatin (R-GemOx) (hazard ratio [HR] 0.41, 95% confidence interval [CI]: 0.28–0.61; p<0.0001) and a three-times longer median PFS at 11.5 months (95% CI: 5.6-17.6), compared to 3.8 months for R-GemOx (95% CI: 2.9-4.1). The safety profile of the Lunsumio and Polivy combination was consistent with the known profiles of the individual study medicines. The incidence of cytokine release syndrome events (CRS) in the Lunsumio VELO plus Polivy arm was low, occurring in one in four patients, with less than 5% of patients experiencing Grade 2 or 3 CRS events. Updated data were presented recently at the American Society of Clinical Oncology Annual Meeting and the European Hematology Association Congress, which showed that with longer follow-up, this treatment combination continued to demonstrate clinical benefit in PFS, particularly in the second-line setting, with no new safety signals. LBCL, composed predominantly of DLBCL, is the most common type of non-Hodgkin lymphoma with more than 18,000 new diagnoses each year in the US. While it is generally responsive to treatment in the frontline, as many as 40% of people will relapse or have refractory disease, at which time salvage therapy options are limited and survival is short. Because this stage of disease is time-sensitive, delays caused by referral requirements, inpatient coordination, or complex treatment logistics can have meaningful clinical consequences. The potential new Lunsumio VELO and Polivy combination may address this critical access issue by offering treatment options closer to where a patient lives. Lunsumio is part of Roche’s industry-leading CD20xCD3 bispecific antibody programme. It is designed with the unique needs and preferences of patients in mind, offering the possibility of outpatient treatment and flexibility between intravenous (IV) and subcutaneous administration routes. Lunsumio IV and Lunsumio VELO are approved for people with third-line or later follicular lymphoma (FL). Lunsumio holds the most extensive long-term data for any bispecific antibody in lymphoma. Ongoing development of Lunsumio in combination with other treatments includes the phase III CELESTIMO and MorningLyte studies in second-line or later and frontline FL, respectively. The SUNMO study [NCT05171647] is a phase III, randomised, open-label, multicentre trial evaluating the efficacy and safety of Lunsumio VELO (mosunetuzumab) in combination with intravenously administered Polivy (polatuzumab vedotin) versus MabThera/Rituxan (rituximab) plus gemcitabine and oxaliplatin in patients with relapsed or refractory large B-cell lymphoma who have received at least one prior systemic therapy and are ineligible for autologous stem cell transplant. Outcome measures include progression-free survival and objective response rate (dual primary endpoints), overall survival, duration of objective response, complete response rate, duration of complete response, safety and tolerability, and patient-reported outcomes. Large B-cell lymphomas, composed predominantly of diffuse large B-cell lymphoma (DLBCL), are the most common type of non-Hodgkin lymphoma (NHL) that affect B-cell lymphocytes, a type of white blood cell. DLBCL is a highly aggressive and life-threatening disease. While it is generally responsive to treatment in the frontline, as many as 40% of people will relapse or have refractory disease, at which time salvage therapy options are limited and survival is short. While existing intensive standard-of-care treatments exist, structural, geographical, and clinical access barriers mean that many patients — particularly those in rural communities or receiving care outside of specialised academic transplant centres — face significant burdens and inequities in obtaining timely treatment. Improving treatments earlier in the course of the disease and providing much needed alternative options could help to improve long-term outcomes. Lunsumio is a first-in-class CD20xCD3 T-cell engaging bispecific antibody designed to target CD20 on the surface of B cells and CD3 on the surface of T cells. This dual targeting activates and redirects a patient’s existing T cells to engage and eliminate malignant B cells. Lunsumio is currently approved as a fixed-duration monotherapy for the treatment of adult patients with third-line or later relapsed or refractory follicular lymphoma (FL) in both intravenous and subcutaneous (Lunsumio VELO) formulations. A robust, global development programme is ongoing to explore the clinical utility of Lunsumio earlier in the disease course and in novel combinations, including the phase III CELESTIMO trial in second-line or later FL. Polivy is a first-in-class antibody-drug conjugate (ADC) targeted against CD79b, a protein preferentially expressed on the surface of mature B cells. Polivy binds to CD79b on the lymphoma cells and delivers a cytotoxic chemotherapy agent directly into the cell, inducing cell death via apoptosis while minimising damage to healthy tissue. Polivy is widely approved globally in combination with MabThera/Rituxan (rituximab) plus cyclophosphamide, doxorubicin and prednisone for previously untreated (first-line) diffuse large B-cell lymphoma (DLBCL), as well as in combination with bendamustine and MabThera/Rituxan for relapsed or refractory DLBCL.

Swiss (SMI) Pharma Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Sandoz Group (SWX:SDZ) Stock Could Be 2% Overvalued After Ljubljana Biosimilar Centre Launch

Roche Receives FDA Acceptance for Supplemental Biologics License Application For Lunsumio And Polivy Combination For Relapsed Or Refractory Large B-Cell Lymphoma

GALD: Rising Execution Bar And Rich P/E Will Likely Cap Future Share Upside

Curatis Holding AG Increases Earnings Guidance for the Financial Year 2026

Novartis AG Presents RemIND Data At EAACI Demonstrating Rhapsido Potential As First Targeted Therapy For Chronic Inducible Urticaria

Cosmo Expands European Presence as Glenmark Launches Winlevi for Acne Treatment

Addex Therapeutics Ltd, Annual General Meeting, Jun 29, 2026

Dottikon ES Holding AG, Annual General Meeting, Jul 02, 2026

Still A Binary Phase III Bet on Evenamide

Bioversys Ag Approves Election of Simona Skerjanec as Members of the Board of Directors